Menlo Park, California, United States · Est. 1998 · 150 employees
Corcept Therapeutics is a pharmaceutical company focused on developing and commercializing drugs for serious metabolic, psychiatric, and oncologic disorders, with primary focus on cortisol-related conditions.
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 1 drug with upcoming expirations
Pipeline
By Phase
5 drugs in development
By Therapeutic Area
top 5
R&D Momentum
38/100
Pipeline Velocity
11/100
Trial Completion Rate
90/100
Pipeline Concentration
21/100
Pipeline Freshness
73/100
Strategic Signals
Activity
Details
Company Overview
$3.5B
Mkt Cap
$482.4M
Revenue
$127.7M
Cash
Therapeutic Focus
Recent SEC Filings
8-K
8-K
CORCEPT THERAPEUTICS INC (CORT) (CIK 0001088856)
Pipeline
Regulatory
8-K
Accession: 0001628280-26-050607
8-K
Accession: 0001193125-26-274258
Lifyorli (copackaged) — LIFYORLI (COPACKAGED)
Application NDA220641 (NDA)
CORCEPT THERAPEUTICS INC (CORT) (CIK 0001088856)
Accession: 000-50679
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)